Search Results

You are looking at 1 - 5 of 5 items for :

  • Refine by Access: All x
Clear All
Full access

Management of Adrenocortical Carcinoma

Jonathan R. Strosberg, Gary D. Hammer, and Gerard M. Doherty

Edited by Kerrin G. Robinson

Cortical Carcinoma: analysis of a multiinstitutional series of 129 patients . The ACC Italian Registry Study Group . Surgery 1996 ; 119 : 161 – 170 . 6 Wooten MD King DK . Adrenal cortical carcinoma. Epidemiology and treatment with mitotane

Full access

NCCN Guidelines® Updates: Neuroendocrine and Adrenal Tumors

“Consider adjuvant mitotane therapy (category 3).” • Treatment, following Locoregional unresectable or Metastatic disease, the following options were revised: ➤ First bullet was revised: “Consider observation with chest CT ± contrast and abdominal/pelvic CT

Full access

Neuroendocrine Tumors

Matthew H. Kulke, Al B. Benson III, Emily Bergsland, Jordan D. Berlin, Lawrence S. Blaszkowsky, Michael A. Choti, Orlo H. Clark, Gerard M. Doherty, James Eason, Lyska Emerson, Paul F. Engstrom, Whitney S. Goldner, Martin J. Heslin, Fouad Kandeel, Pamela L. Kunz, Boris W. Kuvshinoff II, Jeffrey F. Moley, Venu G. Pillarisetty, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata, Jonathan R. Strosberg, Jean-Nicolas Vauthey, Rebekah White, James C. Yao, Deborah A. Freedman-Cass, and Mary A. Dwyer

corticosteroid supplementation. If cortisol production is symmetric, medical management is indicated. Medical management of hypercortisolism is achieved with adrenostatic agents, including ketoconazole and mitotane. Ketoconazole is most commonly used (at doses

Full access

Neuroendocrine and Adrenal Tumors, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology

Manisha H. Shah, Whitney S. Goldner, Al B. Benson III, Emily Bergsland, Lawrence S. Blaszkowsky, Pamela Brock, Jennifer Chan, Satya Das, Paxton V. Dickson, Paul Fanta, Thomas Giordano, Thorvardur R. Halfdanarson, Daniel Halperin, Jin He, Anthony Heaney, Martin J. Heslin, Fouad Kandeel, Arash Kardan, Sajid A. Khan, Boris W. Kuvshinoff II, Christopher Lieu, Kimberly Miller, Venu G. Pillarisetty, Diane Reidy, Sarimar Agosto Salgado, Shagufta Shaheen, Heloisa P. Soares, Michael C. Soulen, Jonathan R. Strosberg, Craig R. Sussman, Nikolaos A. Trikalinos, Nataliya A. Uboha, Namrata Vijayvergia, Terence Wong, Beth Lynn, and Cindy Hochstetler

achieve negative margins and avoid breaching the tumor capsule. Because of the rarity of ACCs, no randomized, prospective trials of adjuvant therapy have been published. Most retrospective reports have examined the use of adjuvant mitotane, an oral

Full access

Benefit of Postoperative Radiotherapy for Patients With Nonmetastatic Adrenocortical Carcinoma: A Population-Based Analysis

Kan Wu, Xu Liu, Zhihong Liu, Yiping Lu, Xianding Wang, and Xiang Li

recurrence, leading to a poor prognosis. 4 Therefore, there is an urgent need for adjuvant treatment intensification to prevent disease recurrence and improve survival outcomes. Currently, mitotane monotherapy, cytotoxic drugs, and radiotherapy (RT) are